Yifei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yifei Huang has a total of 324 co-authors. Here are the top co-authors by number of shared publications:
- Liqiang Wang
Department of Ophthalmology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
57 shared publications Qun Wang
Senior Department of Ophthalmology, Chinese People's Liberation Army General Hospital, Beijing, China
15 shared publications- Ye Tao
Department of Ophthalmology, Henan eye institute, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, China
13 shared publications - Da-Jiang Wang
Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
10 shared publications Liqiang Wang
10 shared publicationsYong Liu
Air force medical center of Chinese PLA, Beijing, China
10 shared publications
Latest Publications
- 26 March 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (6) , 1336-1356
Growth Differentiation Factor 11 Promotes Corneal Endothelial Injury Repair by Activating the SRY-Box Transcription Factor 9–β-Catenin Signaling Pathway
- 26 March 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (6) , 1336-1356
Growth Differentiation Factor 11 Promotes Corneal Endothelial Injury Repair by Activating the SRY-Box Transcription Factor 9–β-Catenin Signaling Pathway
- Open Access
- 21 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2848
Unveiling Systemic Biomarkers and Metabolic Mechanisms in Glaucoma Progression from Multi-Omics Insights
Early diagnosis of glaucoma remains challenging due to its asymptomatic onset and multifactorial pathological mechanisms. Growing evidence indicates that metabolic disorders and systemic molecular alterations play significant roles in glaucoma pathogenesis. However, reliable biomarkers and corresponding specific mechanisms remain unclear. In this study, we employed a multi-omics approach that encompassed metabolomics, transcriptomics, and Mendelian randomization to investigate the association between glaucoma and 35 types of blood and urine biomarkers. Metabolic pathway analysis was conducted using pathway enrichment analysis of differentially expressed genes based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Our study indicated that glaucoma contributed to elevated calcium concentration (OR = 1.044, 95% CI: 1.002–1.088, p = 0.039) in blood and urine, mediated by cell membrane calcium channels and calcium release from intracellular storage. Conversely, glucose was found to contribute to high glaucoma risk (OR = 1.324, 95% CI: 1.143–1.533, p = 0.0002), mediated by increased aqueous humor production, elevated intraocular pressure, endoplasmic reticulum stress, and oxidative stress. Validation experiments showed that calcium levels in blood, urine, and retina were elevated in the glaucoma group, and elevated glucose levels significantly reduced the 661W cell viability and induced apoptosis. This study offers new insights into the specific mechanisms linking blood and urine biomarkers to glaucoma, contributing to its prevention and screening.
- 21 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2848
Open AccessUnveiling Systemic Biomarkers and Metabolic Mechanisms in Glaucoma Progression from Multi-Omics Insights
Early diagnosis of glaucoma remains challenging due to its asymptomatic onset and multifactorial pathological mechanisms. Growing evidence indicates that metabolic disorders and systemic molecular alterations play significant roles in glaucoma pathogenesis. However, reliable biomarkers and corresponding specific mechanisms remain unclear. In this study, we employed a multi-omics approach that encompassed metabolomics, transcriptomics, and Mendelian randomization to investigate the association between glaucoma and 35 types of blood and urine biomarkers. Metabolic pathway analysis was conducted using pathway enrichment analysis of differentially expressed genes based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Our study indicated that glaucoma contributed to elevated calcium concentration (OR = 1.044, 95% CI: 1.002–1.088, p = 0.039) in blood and urine, mediated by cell membrane calcium channels and calcium release from intracellular storage. Conversely, glucose was found to contribute to high glaucoma risk (OR = 1.324, 95% CI: 1.143–1.533, p = 0.0002), mediated by increased aqueous humor production, elevated intraocular pressure, endoplasmic reticulum stress, and oxidative stress. Validation experiments showed that calcium levels in blood, urine, and retina were elevated in the glaucoma group, and elevated glucose levels significantly reduced the 661W cell viability and induced apoptosis. This study offers new insights into the specific mechanisms linking blood and urine biomarkers to glaucoma, contributing to its prevention and screening.
- Open Access
- 20 January 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 63
Hydrogen-rich saline treatment modulates proteomic profiles to mitigate cataract development in a N-methyl-N-nitrosourea-induced rat model
Purpose: Cataracts are associated with oxidative stress-induced damage to lens proteins. This study aims to identify differentially expressed proteins (DEPs) associated with the protective effects of hydrogen-rich saline (HRS) against N-methyl-N-nitrosourea (MNU)-induced cataracts, utilizing the antioxidant properties of hydrogen. Methods: Sprague–Dawley rats were assigned to control, MNU-only, MNU + normal saline (NS), MNU + pirenoxine(PRX), and MNU + HRS groups. Cataracts were induced with MNU (postnatal day 15), and treatments (postnatal days 8–21) included intraperitoneal injections and eye drops. Cataract severity was assessed using slit-lamp examinations, Pentacam analysis, and spectrophotometry. Proteomic analysis of lens tissues from the MNU + HRS and MNU + NS groups employed tandem mass tag (TMT) labeling and mass spectrometry. DEPs were identified, grouped based on fold changes, and analyzed for Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG),, and domain enrichment. Parallel reaction monitoring (PRM) validated selected DEPs. Results: HRS reduced MNU-induced cataract incidence to 50% versus 100% in MNU-only and NS groups and preserved lens clarity comparable to normal controls. Proteomic analysis identified 90 upregulated and 303 downregulated proteins in the HRS-treated group versus the NS-treated group. DEPs were enriched in GO terms related to ion transport, homeostasis, and ATP hydrolysis, as well as KEGG pathways like oxidative phosphorylation and arginine biosynthesis. Domain enrichment showed links to ATPase activity and energy metabolism. DEPs were grouped into Q1–Q4, with Q1 showing enrichment in oxidative phosphorylation and metabolic pathways. PRM confirmed the downregulation of 14 stress-response and metabolic proteins in the HRS-treated group. Conclusion: HRS mitigates MNU-induced cataracts possibly by reducing oxidative stress and downregulating stress-response and metabolic proteins.
- 20 January 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 63
Open AccessHydrogen-rich saline treatment modulates proteomic profiles to mitigate cataract development in a N-methyl-N-nitrosourea-induced rat model
Purpose: Cataracts are associated with oxidative stress-induced damage to lens proteins. This study aims to identify differentially expressed proteins (DEPs) associated with the protective effects of hydrogen-rich saline (HRS) against N-methyl-N-nitrosourea (MNU)-induced cataracts, utilizing the antioxidant properties of hydrogen. Methods: Sprague–Dawley rats were assigned to control, MNU-only, MNU + normal saline (NS), MNU + pirenoxine(PRX), and MNU + HRS groups. Cataracts were induced with MNU (postnatal day 15), and treatments (postnatal days 8–21) included intraperitoneal injections and eye drops. Cataract severity was assessed using slit-lamp examinations, Pentacam analysis, and spectrophotometry. Proteomic analysis of lens tissues from the MNU + HRS and MNU + NS groups employed tandem mass tag (TMT) labeling and mass spectrometry. DEPs were identified, grouped based on fold changes, and analyzed for Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG),, and domain enrichment. Parallel reaction monitoring (PRM) validated selected DEPs. Results: HRS reduced MNU-induced cataract incidence to 50% versus 100% in MNU-only and NS groups and preserved lens clarity comparable to normal controls. Proteomic analysis identified 90 upregulated and 303 downregulated proteins in the HRS-treated group versus the NS-treated group. DEPs were enriched in GO terms related to ion transport, homeostasis, and ATP hydrolysis, as well as KEGG pathways like oxidative phosphorylation and arginine biosynthesis. Domain enrichment showed links to ATPase activity and energy metabolism. DEPs were grouped into Q1–Q4, with Q1 showing enrichment in oxidative phosphorylation and metabolic pathways. PRM confirmed the downregulation of 14 stress-response and metabolic proteins in the HRS-treated group. Conclusion: HRS mitigates MNU-induced cataracts possibly by reducing oxidative stress and downregulating stress-response and metabolic proteins.
- Open Access
- 9 January 2026
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 6 (1) , 80-86
Mihe (MIOK) KPro with auricular cartilage reinforcement in end-stage corneal blindness: An open-label, nonrandomized trial
- 9 January 2026
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 6 (1) , 80-86
Open AccessMihe (MIOK) KPro with auricular cartilage reinforcement in end-stage corneal blindness: An open-label, nonrandomized trial
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1)
Precision of Pachymetry Measured With a Portable High‐Resolution Ultrasound, a Standard Ultrasound, and Two Scheimpflug Pachymeters
Subject: To assess the precision (repeatability and reproducibility) and agreement of central corneal thickness (CCT) measurements by a high‐resolution ultrasound (E‐pach), a standard ultrasound, and two Scheimpflug pachymeters in healthy eyes. Methods: Instrument diagnostic test study. A total of 100 healthy volunteers were enrolled to measure right‐eye CCT by a high‐resolution ultrasound (E‐pach), a standard ultrasound (A‐scan device), and two Scheimpflug pachymeters (Pentacam and Corvis ST). To assess repeatability and reproducibility, the test−retest repeatability (TRT) and intraclass correlation coefficient (ICC) were calculated. The agreement among the four devices was evaluated with Bland−Altman plots. Results: The high‐resolution ultrasound (E‐pach) showed repeatability (ICC = 0.9981), interobserver reproducibility (ICC = 0.9971), and intersession reproducibility (ICC = 0.9825); the standard ultrasound and two Scheimpflug pachymeters also showed similar repeatability (all ICC ≥ 0.9679), interobserver reproducibility (all ICC ≥ 0.9730), and intersession reproducibility (all ICC ≥ 0.9647). However, the high‐resolution ultrasound yielded CCT values that were obviously lower than those of the standard ultrasound and Pentacam ( p < 0.001) but higher than those of the Corvis ST ( p < 0.001). The 95% limits of agreement (LoA) in the Bland−Altman plots were 44.5 µm (high‐resolution ultrasound vs. standard ultrasound), 34.9 µm (high‐resolution ultrasound vs. Corvis CT), and 32.5 µm (high‐resolution ultrasound vs. Pentacam). Conclusions: The high‐resolution ultrasound is a portable, reliable, and inexpensive pachymeter. However, the CCT values obtained from the high‐resolution ultrasound are not interchangeable with those from Pentacam, Corvis ST, and standard ultrasound.
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1)
Open AccessPrecision of Pachymetry Measured With a Portable High‐Resolution Ultrasound, a Standard Ultrasound, and Two Scheimpflug Pachymeters
Subject: To assess the precision (repeatability and reproducibility) and agreement of central corneal thickness (CCT) measurements by a high‐resolution ultrasound (E‐pach), a standard ultrasound, and two Scheimpflug pachymeters in healthy eyes. Methods: Instrument diagnostic test study. A total of 100 healthy volunteers were enrolled to measure right‐eye CCT by a high‐resolution ultrasound (E‐pach), a standard ultrasound (A‐scan device), and two Scheimpflug pachymeters (Pentacam and Corvis ST). To assess repeatability and reproducibility, the test−retest repeatability (TRT) and intraclass correlation coefficient (ICC) were calculated. The agreement among the four devices was evaluated with Bland−Altman plots. Results: The high‐resolution ultrasound (E‐pach) showed repeatability (ICC = 0.9981), interobserver reproducibility (ICC = 0.9971), and intersession reproducibility (ICC = 0.9825); the standard ultrasound and two Scheimpflug pachymeters also showed similar repeatability (all ICC ≥ 0.9679), interobserver reproducibility (all ICC ≥ 0.9730), and intersession reproducibility (all ICC ≥ 0.9647). However, the high‐resolution ultrasound yielded CCT values that were obviously lower than those of the standard ultrasound and Pentacam ( p < 0.001) but higher than those of the Corvis ST ( p < 0.001). The 95% limits of agreement (LoA) in the Bland−Altman plots were 44.5 µm (high‐resolution ultrasound vs. standard ultrasound), 34.9 µm (high‐resolution ultrasound vs. Corvis CT), and 32.5 µm (high‐resolution ultrasound vs. Pentacam). Conclusions: The high‐resolution ultrasound is a portable, reliable, and inexpensive pachymeter. However, the CCT values obtained from the high‐resolution ultrasound are not interchangeable with those from Pentacam, Corvis ST, and standard ultrasound.
- 1 November 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (6) , 069501
Corrigendum: 3D biomaterial P scaffolds carrying umbilical cord mesenchymal stem cells improve biointegration of keratoprosthesis (2022 Biomed. Mater. 17 055004)
- 1 November 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (6) , 069501
Corrigendum: 3D biomaterial P scaffolds carrying umbilical cord mesenchymal stem cells improve biointegration of keratoprosthesis (2022 Biomed. Mater. 17 055004)
- Open Access
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1630425
A preliminary study on the clinical characteristics of lacrimal duct obstruction in patients with a history of anterior uveitis
Aim: This study aimed to investigate the clinical features of lacrimal duct obstruction (LDO) in patients with a history of anterior uveitis (AU) and explore preventive strategies by analyzing their demographic, anatomical, and surgical outcome profiles.Methods: We retrospectively reviewed 40 LDO patients (58 eyes) with a history of AU, treated between 2020 and 2024, comparing them to non-AU LDO controls. Data included demographics, AU–epiphora temporal relationships, obstruction characteristics (location, extent, and adhesions), and surgical outcomes. Statistical analysis evaluated differences between groups.Results: The mean age was 49.88 ± 10.18 years, with 30 women (75%) and 10 men (25%). Proximal lacrimal canalicular obstruction (p < 0.001), with extensive adhesions observed intraoperatively in 80% of uveitis cases.Conclusion: In patients with a history of AU, LDO predominantly affects the proximal lacrimal structures, often resulting in severe adhesions and poor surgical outcomes, with a cure rate of only 20%. The temporal link between epiphora and AU onset suggests shared pathophysiology. Targeted research is critical to clarify AU-LDO mechanisms and optimize prevention.
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1630425
Open AccessA preliminary study on the clinical characteristics of lacrimal duct obstruction in patients with a history of anterior uveitis
Aim: This study aimed to investigate the clinical features of lacrimal duct obstruction (LDO) in patients with a history of anterior uveitis (AU) and explore preventive strategies by analyzing their demographic, anatomical, and surgical outcome profiles.Methods: We retrospectively reviewed 40 LDO patients (58 eyes) with a history of AU, treated between 2020 and 2024, comparing them to non-AU LDO controls. Data included demographics, AU–epiphora temporal relationships, obstruction characteristics (location, extent, and adhesions), and surgical outcomes. Statistical analysis evaluated differences between groups.Results: The mean age was 49.88 ± 10.18 years, with 30 women (75%) and 10 men (25%). Proximal lacrimal canalicular obstruction (p < 0.001), with extensive adhesions observed intraoperatively in 80% of uveitis cases.Conclusion: In patients with a history of AU, LDO predominantly affects the proximal lacrimal structures, often resulting in severe adhesions and poor surgical outcomes, with a cure rate of only 20%. The temporal link between epiphora and AU onset suggests shared pathophysiology. Targeted research is critical to clarify AU-LDO mechanisms and optimize prevention.
- Open Access
- 29 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
Reln-Dab1 pathway mitigates retinal ganglion cell apoptosis in retinal ischemia-reperfusion injury
Ischemia-reperfusion (I/R) injury is associated with a variety of retinal diseases, resulting in loss of the number of ganglion cells (RGCs), retinal structural disorders, and retinal dysfunction. The Reelin protein is an important regulator of neuronal migration and synaptogenesis, and the Reln signaling pathway plays an essential role in regulating the targeted projection of RGC dendrites and neuronal survival, which has not been reported in retinal I/R injury. The aim of this study was to investigate the expression, role and mechanism of Reln in retinal I/R injury. By establishing Reln-CreERT2 mTmG transgenic mice, it was observed that the expression of Reln initially decreased and then increased after retinal I/R injury. After supplementing exogenous Reelin protein and adeno-associated virus (AAV)-targeted regulation of Reln in vivo, morphological and functional experiments demonstrated its effectiveness in protecting RGCs survival, maintaining morphological integrity of the retina, and inhibiting post-injury retinal dysfunction. Furthermore, integrin β1 (Itgb1) was identified as the main receptor through which Reelin exerts neuroprotective effects while regulating retinal I/R injury repair through the Dab1-PI3K-Akt pathway. These findings provide evidence supporting Reln pathway’s role in maintaining retinal homeostasis and facilitating injury repair. Moreover, these findings have significant implications for identifying new targets for preventing and treating various retinal diseases.
- 29 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
Open AccessReln-Dab1 pathway mitigates retinal ganglion cell apoptosis in retinal ischemia-reperfusion injury
Ischemia-reperfusion (I/R) injury is associated with a variety of retinal diseases, resulting in loss of the number of ganglion cells (RGCs), retinal structural disorders, and retinal dysfunction. The Reelin protein is an important regulator of neuronal migration and synaptogenesis, and the Reln signaling pathway plays an essential role in regulating the targeted projection of RGC dendrites and neuronal survival, which has not been reported in retinal I/R injury. The aim of this study was to investigate the expression, role and mechanism of Reln in retinal I/R injury. By establishing Reln-CreERT2 mTmG transgenic mice, it was observed that the expression of Reln initially decreased and then increased after retinal I/R injury. After supplementing exogenous Reelin protein and adeno-associated virus (AAV)-targeted regulation of Reln in vivo, morphological and functional experiments demonstrated its effectiveness in protecting RGCs survival, maintaining morphological integrity of the retina, and inhibiting post-injury retinal dysfunction. Furthermore, integrin β1 (Itgb1) was identified as the main receptor through which Reelin exerts neuroprotective effects while regulating retinal I/R injury repair through the Dab1-PI3K-Akt pathway. These findings provide evidence supporting Reln pathway’s role in maintaining retinal homeostasis and facilitating injury repair. Moreover, these findings have significant implications for identifying new targets for preventing and treating various retinal diseases.
- 7 April 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-9
Wnt7a can upregulate cell adhesion and migration related genes expression and facilitate the repair of corneal epithelial cells after injury
Purpose To investigate the role of Wnt7a in corneal epithelial repair and its underlying mechanisms. Methods Immunohistochemistry and immunofluorescence were used to assess Wnt7a expression in mouse corneas under normal and injury conditions. Human corneal epithelial cells (HCECs) were treated with Wnt7a siRNA or recombinant human Wnt7a (rhWnt7a) to evaluate proliferation (CCK-8 assay) and migration (scratch assay). Transcriptome sequencing and western blotting were performed to identify Wnt7a-regulated pathways and proteins. Results Under normal conditions, Wnt7a was predominantly localized to the corneal limbus basal cells. Following corneal injury, its expression significantly increased in central corneal epithelial cells and co-localized with nuclei during repair. Wnt7a siRNA suppressed HCEC proliferation and migration, while rhWnt7a enhanced proliferation. Transcriptome analysis revealed upregulation of cell adhesion-related genes (e.g., FN1, ITGBs, LAMs), particularly fibronectin (FN), validated by increased FN protein levels after rhWnt7a treatment. Pathway enrichment implicated PI3K/Akt, Wnt signaling, and ECM-receptor interactions. Conclusion Wnt7a promotes corneal epithelial repair by enhancing migration and proliferation, primarily through upregulating fibronectin and ECM-related pathways. These findings highlight Wnt7a as a potential therapeutic target for accelerating corneal wound healing.
- 7 April 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-9
Wnt7a can upregulate cell adhesion and migration related genes expression and facilitate the repair of corneal epithelial cells after injury
Purpose To investigate the role of Wnt7a in corneal epithelial repair and its underlying mechanisms. Methods Immunohistochemistry and immunofluorescence were used to assess Wnt7a expression in mouse corneas under normal and injury conditions. Human corneal epithelial cells (HCECs) were treated with Wnt7a siRNA or recombinant human Wnt7a (rhWnt7a) to evaluate proliferation (CCK-8 assay) and migration (scratch assay). Transcriptome sequencing and western blotting were performed to identify Wnt7a-regulated pathways and proteins. Results Under normal conditions, Wnt7a was predominantly localized to the corneal limbus basal cells. Following corneal injury, its expression significantly increased in central corneal epithelial cells and co-localized with nuclei during repair. Wnt7a siRNA suppressed HCEC proliferation and migration, while rhWnt7a enhanced proliferation. Transcriptome analysis revealed upregulation of cell adhesion-related genes (e.g., FN1, ITGBs, LAMs), particularly fibronectin (FN), validated by increased FN protein levels after rhWnt7a treatment. Pathway enrichment implicated PI3K/Akt, Wnt signaling, and ECM-receptor interactions. Conclusion Wnt7a promotes corneal epithelial repair by enhancing migration and proliferation, primarily through upregulating fibronectin and ECM-related pathways. These findings highlight Wnt7a as a potential therapeutic target for accelerating corneal wound healing.
- Open Access
- 1 April 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (4) , 36
Proliferator–Activated Receptor Alpha Inhibits Abnormal Extracellular Matrix Accumulation and Maintains Energy Metabolism in Late-Onset Fuchs Endothelial Corneal Dystrophy
Fuchs endothelial corneal dystrophy (FECD) is the most common corneal endothelial dystrophy and guttae are crucial in causing progressive loss of corneal endothelium. This study aimed to find a way to inhibit the formation of guttae in FECD. Mitochondria fatty acid β-oxidation (FAO) and tricarboxylic acid (TCA) cycle processes were negatively enriched in the FECD group according to gene set enrichment analysis in GSE171830. In vivo UV-A-induced late-onset FECD mouse model were established. After irradiation, aged proliferator-activated receptor alpha (PPARα-/-) mice manifested greater corneal opacity, cornea edema, and varied corneal endothelial cell morphology compared with wild-type mice. The total metabolites in cornea of aged PPARα-/- mice and wild-type mice were detected by mass spectrometry. Metabolites of the FAO pathway were decreased in corneas of PPARα-/- mice, coincident with enzymes of FAO decreased in GSE171830. The score for FAO energy metabolism was negatively related to that of the TGF-β pathway according to gene set variation analysis. The express of alpha smooth muscle actin (αSMA) and Col1a were increased in aged PPARα-/- mice and small interfering PPARα B4G12 cell lines. After irradiation, activation or overexpression of PPARα demonstrated reduced corneal endothelial damage and reversal of Descemet membrane thickening, along with downregulation of fibrosis-related genes such as αSMA and collagen type I alpha 1 (Col1a). In vitro experiments revealed that fenofibrate could reverse fibrosis and damage of cell-to-cell connections induced by TGF-β. Additionally, fenofibrate was found to alleviate mitochondrial damage in B4G12 and increase oxygen consumption rates after TGF-β treatment. Overall, we suggested that the overexpression or activation of PPARα can inhibit FAO energy dysfunction of corneal endothelium and the abnormal extracellular matrix formation in Descemet's membrane, which is the primary pathology of FECD. Thus, PPARα may be a potential target for attenuating the progression of FECD.
- 1 April 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (4) , 36
Open AccessProliferator–Activated Receptor Alpha Inhibits Abnormal Extracellular Matrix Accumulation and Maintains Energy Metabolism in Late-Onset Fuchs Endothelial Corneal Dystrophy
Fuchs endothelial corneal dystrophy (FECD) is the most common corneal endothelial dystrophy and guttae are crucial in causing progressive loss of corneal endothelium. This study aimed to find a way to inhibit the formation of guttae in FECD. Mitochondria fatty acid β-oxidation (FAO) and tricarboxylic acid (TCA) cycle processes were negatively enriched in the FECD group according to gene set enrichment analysis in GSE171830. In vivo UV-A-induced late-onset FECD mouse model were established. After irradiation, aged proliferator-activated receptor alpha (PPARα-/-) mice manifested greater corneal opacity, cornea edema, and varied corneal endothelial cell morphology compared with wild-type mice. The total metabolites in cornea of aged PPARα-/- mice and wild-type mice were detected by mass spectrometry. Metabolites of the FAO pathway were decreased in corneas of PPARα-/- mice, coincident with enzymes of FAO decreased in GSE171830. The score for FAO energy metabolism was negatively related to that of the TGF-β pathway according to gene set variation analysis. The express of alpha smooth muscle actin (αSMA) and Col1a were increased in aged PPARα-/- mice and small interfering PPARα B4G12 cell lines. After irradiation, activation or overexpression of PPARα demonstrated reduced corneal endothelial damage and reversal of Descemet membrane thickening, along with downregulation of fibrosis-related genes such as αSMA and collagen type I alpha 1 (Col1a). In vitro experiments revealed that fenofibrate could reverse fibrosis and damage of cell-to-cell connections induced by TGF-β. Additionally, fenofibrate was found to alleviate mitochondrial damage in B4G12 and increase oxygen consumption rates after TGF-β treatment. Overall, we suggested that the overexpression or activation of PPARα can inhibit FAO energy dysfunction of corneal endothelium and the abnormal extracellular matrix formation in Descemet's membrane, which is the primary pathology of FECD. Thus, PPARα may be a potential target for attenuating the progression of FECD.